Scienture Holdings Inc (SCNX) Stock Price, Quote & News

Latest News on SCNX

Apr 22, 2025, 8:05 AM EDT - 16 days ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 8, 2025, 8:05 AM EDT - 4 weeks ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 3, 2025, 8:26 AM EDT - 5 weeks ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Mar 25, 2025, 8:05 AM EDT - 6 weeks ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 19, 2025, 8:05 AM EDT - 7 weeks ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 18, 2025, 8:05 AM EDT - 7 weeks ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 6, 2025, 7:40 AM EST - 2 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Jan 21, 2025, 8:05 AM EST - 3 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Dec 17, 2024, 8:05 AM EST - 5 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 10, 2024, 8:05 AM EST - 5 months ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Sep 24, 2024, 8:01 AM EDT - 8 months ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 20, 2024, 11:59 AM EDT - 8 months ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Aug 5, 2024, 8:01 AM EDT - 9 months ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Jul 26, 2024, 8:01 AM EDT - 10 months ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 9, 2024, 8:05 AM EDT - 10 months ago

TRxADE Health, Inc. Announces Special Cash Dividend

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

Nov 29, 2023, 6:13 PM EST - 1 year ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Oct 17, 2023, 8:05 AM EDT - 1 year ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 12, 2023, 8:05 AM EDT - 1 year ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 4, 2023, 8:05 AM EDT - 1 year ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Sep 7, 2023, 9:00 AM EDT - 1 year ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 6, 2023, 9:45 AM EDT - 1 year ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Aug 24, 2023, 8:05 AM EDT - 1 year ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 22, 2023, 8:05 AM EDT - 1 year ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 14, 2023, 10:25 AM EDT - 1 year ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 3, 2023, 9:05 AM EDT - 1 year ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Jul 31, 2023, 4:15 PM EDT - 1 year ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 8:35 AM EDT - 1 year ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 1 year ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

May 15, 2023, 10:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

May 15, 2023, 5:00 PM EDT - 2 years ago

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

May 5, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

Apr 25, 2023, 12:20 AM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

Mar 27, 2023, 9:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

Mar 27, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results

Mar 13, 2023, 4:00 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.

Dec 6, 2022, 9:00 AM EST - 2 years ago

Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model

Nov 8, 2022, 12:42 AM EST - 2 years ago

TRxADE Health, Inc. (MEDS) Q3 2022 Earnings Call Transcript

Nov 7, 2022, 4:30 PM EST - 2 years ago

TRxADE HEALTH Reports Third Quarter Gross Margin of 58% and Q3 2022 Financial Results

Oct 24, 2022, 3:30 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Third Quarter 2022 Financial Results on Monday, November 7th at 5:00 p.m.

Oct 4, 2022, 6:40 PM EDT - 2 years ago

TRxADE Health Announces Pricing of $1.8 Million Registered Direct Offering

Oct 3, 2022, 9:15 AM EDT - 2 years ago

TRxADE HEALTH, INC. Taps Advisory Board Member and Leading Pharmaceutical Industry Expert, Mr.

Sep 20, 2022, 8:30 AM EDT - 2 years ago

Market Cap	12.01M
Revenue (ttm)	140,000.00
Net Income (ttm)	9.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	6,478.57%
Debt to Equity Ratio	0.01

Volume	27,700
Avg Vol	3,540,294
Day's Range	N/A - N/A
Shares Out	12.52M
Stochastic %K	49%
Beta	2.83
Analysts	Strong Buy
Price Target	N/A